Inside BENEO’s new pulse plant: pioneering sustainable protein from faba beans
Evolva, a global player in sustainable, fermentation-based approaches to ingredients for health, wellness and nutrition announced the US government’s approval of the transfer of the GC-072 contract to Emergent BioSolutions Inc. This triggers a payment of $ 4 million to Evolva, following an initial upfront payment of $ 1.5 million in December 2014. This does not change the revenue guidance for 2015.
In December 2014, Emergent acquired Evolva’s anti-bacterial programme, the EV-035 series in a transaction worth up to $ 70.5 million plus royalties. The lead compound in the EV-035 series is the broad-spectrum antibiotic GC-072, which is being developed with US government biodefense funding. Emergent will now have full responsibility for this contract.
Evolva’s products include stevia, resveratrol, vanillin, nootkatone and saffron. As well as developing its own proprietary ingredients, Evolva also deploys its technology for partners, providing them with a competitive edge and sharing in the returns they make.